Sunshine Biopharma Collaborates For Its Lead MRNA-Based Cancer Program
Sunshine Biopharma Collaborates For Its Lead MRNA-Based Cancer Program
阳光生物制药公司为其基于Lead mRNA的癌症项目提供合作
- Sunshine Biopharma Inc (NASDAQ:SBFM) has entered into a collaboration agreement with a North American lipid nanoparticle (LNP) company to advance the development of its mRNA-based anticancer macromolecule, K1.1.
- The company's collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma's in-house developed antineoplastic mRNA, K1.1.
- Sunshine Biopharma previously showed that its K1.1 mRNA could destroy cancer cells in vitro, including multidrug-resistant breast, ovarian adenocarcinoma, and pancreatic cancer cells.
- Also Read: EXCLUSIVE: Sunshine Biopharma Acquires Canadian Generic Player For $22M
- Parallel studies using normal human cells showed that K1.1 mRNA had little or no cytotoxic effects.
- The partner-generated K1.1a::LNP and K1.1b::LNP will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers and liver cancer.
- The company can rapidly advance to conducting human trials if these mice studies prove successful. The LNP-formulated K1.1 mRNA can be readily adapted for delivery into patients using the mRNA vaccine technology.
- Price Action: SBFM shares are down 0.23% at $0.84 on the last check Wednesday.
- 阳光生物医药公司纳斯达克(Sequoia Capital：SBFM)与北美一家脂质纳米粒子(LNP)公司达成合作协议，推进其基于信使核糖核酸的抗癌大分子K1.1的开发。
- 该公司的合作伙伴将为阳光生物制药公司内部开发的抗肿瘤信使核糖核酸K1.1准备两种LNP配方(K1.1a和K1.1b)。
- 阳光生物制药公司此前曾表明，其K1.1基因在体外可以杀死癌细胞，包括多药耐药乳腺癌细胞、卵巢腺癌和胰腺癌细胞。
- 另请阅读：独家报道：阳光生物医药以2200万美元收购加拿大仿制药公司
- 使用正常人类细胞进行的平行研究表明，K1.1mRNA几乎没有或几乎没有细胞毒性作用。
- 合作伙伴产生的K1.1a：：LNP和K1.1b：：LNP将用于表达体外测试的人类癌症和肝癌的异种移植小鼠的体内研究。
- 如果这些小鼠研究被证明成功，该公司可以迅速推进到进行人体试验。使用信使核糖核酸疫苗技术，LNP配制的K1.1信使核糖核酸可以很容易地用于患者体内。
- 价格行动：在周三的最后一次检查中，SBFM的股价下跌了0.23%，至0.84美元。